Table 1.
Demographic baseline characteristics of the participants.
| Total participants (N=877) |
Breakthrough cases (n=189) |
Post-immunized group (n=688) | p value | |
|---|---|---|---|---|
| Age (Mean ± SD) | 47.7 ± 14.7 | 44.1 ± 13.9 | 48.7 ± 14.4 | <0.001 |
| Sex (n [%of total]) | <0.001 | |||
| Female | 605(68.9%) | 116(61.4%) | 489(71.1%) | |
| Male | 272(31.0%) | 73(38.6%) | 199(28.9%) | |
| Vaccines (n[%of total]) | <0.001 | |||
| BBIBP | 280(31.9%) | 61(32.3%) | 219(31.8%) | |
| CoronaVac | 527(60.1%) | 118(62.4%) | 409(59.4%) | |
| BBIBP&CoronaVac | 70(7.9%) | 10(5.3%) | 60(8.7%) | |
| Booster vaccination (n [%of total]) | <0.001 | |||
| Yes | 95(10.9%) | 92(48.7%) | 3(0.4%) | |
| No | 781(89.1%) | 97(51.3%) | 684(99.6%) | |
| Time from vaccination to symptom onset (days [IQR]) | — | |||
| Two doses | 215(202-259) | 215(202-259) | — | |
| Booster dose | 63(28-93) | 63(28-93) | — | |
| Clinical classification (n [%of total]) | — | |||
| Mild | 41(4.6%) | 41(21.9%) | — | |
| Moderate | 52(5.9%) | 52(27.5%) | — | |
| Asymptomatic | 96(10.9%) | 96(50.6%) | — |